Mission

The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

About Prostate Cancer

It is the most commonly diagnosed type of cancer for men in Massachusetts.

1 in 7 men will be diagnosed with prostate cancer during their lifetime.

Prostate cancer is the most common (non-skin) cancer in American men, representing 33% of all new cases.

In Boston, prostate cancer has emerged as the most lethal malignancy in African American men. (Boston Public Health Commission)

Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.

It is estimated that in 2019, there will be 174,650 new cases of prostate cancer diagnosed and that close to 31,620 men will die of the disease. Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer are still alive today.

About MPCC

MPCC is a nonprofit organization 501(c)(3) public charity founded in 2001.

MPCC has more than 2000 members and friends of the organization.

MPCC’s board is made up of survivors, medical professionals, representatives of related organizations, and others interested in prostate cancer research, diagnosis, and treatment.

MPCC is guided, in part, by a distinguished Medical Advisory Committee with representatives from leading hospitals and health care providers in the Commonwealth.

MPCC is a participant in the National Alliance of State Prostate Cancer Coalitions (NASPPC).

Board of Directors

Allen L. Snyder III, chairman Northwestern Mutual
Garth Greimann, secretary & treasurer
Arnold Barron — emeritus
Lynn A. Basilio, American Cancer Society
John Carberry, Charles River Mortgage Company, Inc.
Les Cavicchi, Greater Boston Urology, LLC
Jason A. Efstathiou, MD, DPhil, Massachusetts General Hospital
Neal F. Finnegan — emeritus
David S. Godkin, Birnbaum & Godkin, LLP
Mark Anthony Hunter, The Goddard School
Robert Kretschmar, Global Capital Resources, Inc.
Robert S. Lyons — emeritus
Tiffany Nagle, Cullari Communications Global
C. Kirk Neison
Avi Nelson
Dalton A. Skerritt, CEHSID

Medical Advisory Committee

Richard K. Babayan, MD, Boston Medical Center
Glenn J. Bubley, MD, Beth Israel Deaconess Medical Center
J. Jacques Carter, MD, MPH, Beth Israel Deaconess Medical Center
Jason R. Gee, MD, Emerson Urology Associates
Adam Kibel, MD, Brigham and Women’s Hospital
Richard Jaebong Lee, MD, Massachusetts General Hospital
Paul Nguyen, MD, Brigham and Women’s Hospital
William U. Shipley, MD, Massachusetts General Hospital
Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute

Symposium Planning Committee

Anita Christie, Massachusetts Department of Public Health
Judy Green, Massachusetts Prostate Cancer Coalition
Mark Kennedy, Boston Public Health Commission
Tiffany Nagle, Cullari Communications Global
Joanne Pokaski, Beth Israel Deaconess Medical Center
Dalton A. Skerritt, CEHSID
Allen L. Snyder III, Northwestern Mutual
William Tinney, Support Group Leader

BOTTOM